Eligibility:
Purpose: This study helps to identify family members of people with T1D who might have antibodies associated with T1D. Relatives of people with T1D have a 3-4 percent chance of testing positive for antibodies. If participants are found to be antibody positive they will be offered follow up screening and further tests to determine their risk for T1D. Depending on the outcome of those tests, participants may qualify for prevention studies offered by TrialNet.
For more information visit TrialNet on the web.
Coordinators: Juanita O'Brian, CMA, CCRC; Henry Rodriguez, MD
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-9817
Eligibility:
Purpose: To evaluate
the safety and efficacy of immunotherapy with multiple peptides.
Coordinator: Gregory Spires, BSN, RN, CRC
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-9536
Eligibility:
Purpose: To identify a safe, metabolically favorable, dosing regimen for siplizumab that induces changes in T cell phenotypes observed with alefacept therapy
Coordinator: Gregory Spires, BSN, RN, CRC
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-9536
Eligibility:
Purpose: To demonstrate that the efficacy of Afrezza is noninferior to rapid-acting insulin analog (RAA) injections, when both are in combination with a basal insulin.
Coordinator: Gregory Spires, BSN, RN, CRC
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-9536
Eligibility:
Purpose: To evaluation the safety of an Advanced Hybrid
Closed Loop System Using Lyumjev with the Tandem t:slim X2 with Control-IQ
Coordinator: Janet Rodriguez, BSN, RN, CDCES, CRA-USF/ADVANCED
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-5499
Eligibility:
Purpose: The purpose of this study is to
evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in
adult and pediatric patients with type 1 diabetes in the home setting.
After-market
study of the 770G
1 year
randomized first 6 months (current therapy or HCL) followed by 6 months of HCL
Requires
Computer & Internet
Pump,
sensor, meter and all pump/sensor/testing supplies provided for the duration of
the study.
Coordinator: Janet Rodriguez, BSN, RN, CDCES, CRA-USF/ADVANCED
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-5499
Eligibility:
Purpose: This study is evaluating the safety of non-adjunctive CGM use in CGM-naïve participants, by assessing the number of hypoglycemic (Hypo) and diabetic ketoacidosis (DKA) events with use of CGM.
Coordinators: Janet Rodriguez, BSN, RN, CDCES, CRA-USF/ADVANCED; Henry Rodriguez, MD
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-5499
Eligibility:
Purpose: To develop a new model
of care for Latino patients that will provide them with culturally sensitive care.
Coordinator: Janet Rodriguez, BSN, RN, CDCES, CRA-USF/ADVANCED
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-5499
Eligibility:
Purpose: This study is evaluating the safety of non-adjunctive CGM
use in CGM-naïve participants, by assessing the number of hypoglycemic
(Hypo) and diabetic ketoacidosis (DKA) events with use of CGM
Coordinators: Janet Rodriguez, BSN, RN, CDCES, CRA-USF/ADVANCED; Henry Rodriguez, MD
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-5499
Eligibility:
Purpose: To learn
whether empagliflozin and linagliptin may help control blood sugar levels in
children and adolescents with T2D as
Monotherapy.
Empagliflozin and
Linagliptin are oral drugs that are approved to treat T2D in adults, however,
neither is approved to treat T2D in children & adolescents.
Coordinator: Janet Rodriguez, BSN, RN, CDCES, CRA-USF/ADVANCED
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-5499
Eligibility:
Purpose: To
confirm superiority of oral Semaglutide at the maximum tolerated dose* (3 mg, 7
mg or 14 mg) versus placebo on glycemic control in children and adolescents
(age 10 to <18 years) with type 2 diabetes on a background treatment of
metformin or basal insulin or both.
Coordinator: Juanita O'Brian, NRCMA
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-9817
Eligibility:
Purpose: To demonstrate that the efficacy of Afrezza is noninferior to rapid-acting insulin analog (RAA) injections, when both are in combination with a basal insulin.
Coordinator: Gregory Spires, BSN, RN, CRC
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-9536
Eligibility:
Purpose: To evaluate the effect of setrusumab vs placebo
on reduction in fracture rates, to assess the safety profile of setrusumab, and
to evaluate the immunogenicity of setrusumab for the treatment of participants
with OI.
Coordinator: Gregory Spires, BSN, RN, CRC
Contact: usfdiabetesresearchc@usf.edu | Phone Number: (813) 974-9536
TEDDY Study compares characteristics of children diagnosed with type 1 diabetes before and after age 6
New findings from the international The Environmental Determinants of Diabetes in the Young (TEDDY) study add to the growing body of evidence indicating that type 1 diabetes is not a single disease.
Click here to view full article.
USF Awarded Four-Year, $69.9 Million NIH Grant to Continue Type 1 Diabetes Research
The Environmental Determinants of Diabetes in the Young study is led by USF Health’s Jeffrey Krischer, who has built a worldwide epidemiological hub for T1D research at USF.
Click here to view full article.
Nature highlights USF Health-led TEDDY study as a diabetes research milestone
Click here to view article.
USF Health Informatics Institute contributes to new NIH study indicating that measuring gene expression changes over time may help predict type 1 diabetes progression in at-risk children, and lead to earlier diagnosis of the autoimmune disease.
Click here to read the full article.
